ATE458057T1 - Varianten der faktor-vii- oder -viia-gla-domäne - Google Patents

Varianten der faktor-vii- oder -viia-gla-domäne

Info

Publication number
ATE458057T1
ATE458057T1 AT04738925T AT04738925T ATE458057T1 AT E458057 T1 ATE458057 T1 AT E458057T1 AT 04738925 T AT04738925 T AT 04738925T AT 04738925 T AT04738925 T AT 04738925T AT E458057 T1 ATE458057 T1 AT E458057T1
Authority
AT
Austria
Prior art keywords
variants
factor vii
gla domain
human factor
amino acid
Prior art date
Application number
AT04738925T
Other languages
German (de)
English (en)
Inventor
Jesper Haaning
Kim Andersen
Claus Bornaes
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of ATE458057T1 publication Critical patent/ATE458057T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
AT04738925T 2003-06-19 2004-06-18 Varianten der faktor-vii- oder -viia-gla-domäne ATE458057T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47978003P 2003-06-19 2003-06-19
DKPA200400930 2004-06-15
PCT/DK2004/000428 WO2004111242A1 (en) 2003-06-19 2004-06-18 FACTOR VII OR VIIa GLA DOMAIN VARIANTS

Publications (1)

Publication Number Publication Date
ATE458057T1 true ATE458057T1 (de) 2010-03-15

Family

ID=33553697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04738925T ATE458057T1 (de) 2003-06-19 2004-06-18 Varianten der faktor-vii- oder -viia-gla-domäne

Country Status (23)

Country Link
US (5) US20050164932A1 (OSRAM)
EP (1) EP1644504B8 (OSRAM)
JP (2) JP4915918B2 (OSRAM)
KR (1) KR101191779B1 (OSRAM)
CN (1) CN1839203B (OSRAM)
AT (1) ATE458057T1 (OSRAM)
AU (2) AU2004247799B2 (OSRAM)
BR (1) BRPI0411650A (OSRAM)
CA (1) CA2529828C (OSRAM)
CY (1) CY1109984T1 (OSRAM)
DE (1) DE602004025576D1 (OSRAM)
DK (1) DK1644504T3 (OSRAM)
ES (1) ES2338425T3 (OSRAM)
HR (1) HRP20100264T1 (OSRAM)
IL (1) IL172364A (OSRAM)
MX (1) MXPA05013769A (OSRAM)
NZ (2) NZ544728A (OSRAM)
PL (1) PL1644504T3 (OSRAM)
PT (1) PT1644504E (OSRAM)
RU (1) RU2373282C2 (OSRAM)
SI (1) SI1644504T1 (OSRAM)
WO (1) WO2004111242A1 (OSRAM)
ZA (1) ZA200600539B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
BR0309576A (pt) * 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
ES2386010T3 (es) * 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
KR101191779B1 (ko) 2003-06-19 2013-01-14 맥시겐 홀딩스 엘티디 인자 ⅶ 또는 ⅶ에이 지엘에이 도메인 변종들
JP2008509688A (ja) 2004-08-17 2008-04-03 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 改変ビタミンｋ依存性ポリペプチド
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
JP5147692B2 (ja) 2005-07-13 2013-02-20 ノボ ノルディスク ヘルス ケア アーゲー 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
PL1907540T3 (pl) * 2005-07-22 2013-05-31 Bayer Healthcare Llc Aktywacja czynnika VII w roztworze
ES2515915T3 (es) 2005-09-01 2014-10-30 Novo Nordisk Health Care Ag Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
FR2910969B1 (fr) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
EP1952822A1 (en) * 2007-01-26 2008-08-06 Novo Nordisk A/S Factor VII polypeptides with increased affinity to platelets
NZ593611A (en) 2007-04-13 2012-06-29 Catalyst Biosciences Inc Modified factor vii polypeptides and uses thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010149172A2 (en) 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
DK3165232T3 (da) * 2012-12-24 2019-09-16 Coagulant Therapeutics Corp Faktor vii-polypeptider med kortvarig virkning
JP6595977B2 (ja) * 2013-03-15 2019-10-23 グラディエーター・バイオサイエンシーズ・インコーポレイテッド 治療剤としてのＧｌａドメイン
CN104211802B (zh) * 2013-05-29 2018-07-27 成都渊源生物科技有限公司 人凝血因子轻链蛋白及其应用
ES2943359T3 (es) 2014-12-10 2023-06-12 Opko Biologics Ltd Métodos de producción de polipéptidos de hormona de crecimiento modificados con CTP de acción prolongada
JP2019515904A (ja) * 2016-04-14 2019-06-13 アイコニック セラピューティクス，インコーポレイテッド 新血管新生に関連する障害を治療するための組成物および方法
US11976106B2 (en) 2016-07-11 2024-05-07 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AU2018330427A1 (en) 2017-09-05 2020-04-02 GLAdiator Biosciences, Inc. Method of targeting exosomes
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
JP2799316B2 (ja) 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
DE69101634T4 (de) 1990-01-26 1994-12-01 Immuno Ag Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
WO1991011514A1 (en) 1990-01-29 1991-08-08 Zymogenetics, Inc. Anticoagulant proteins
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) * 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
EP0574402B2 (en) * 1990-11-26 2012-08-01 Genetics Institute, LLC Expression of pace in host cells and methods of use thereof
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
DE69233398D1 (de) 1991-02-28 2004-09-16 Novo Nordisk As Modifizierter faktor-vii
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JPH0720127A (ja) * 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
ES2169074T3 (es) 1993-05-21 2002-07-01 Novo Nordisk Healthcare Ag Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas.
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
DE69735597T2 (de) * 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6608183B1 (en) 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ES2289824T3 (es) 1998-10-30 2008-02-01 Novozymes A/S Proteinas glicosiladas con alergenicidad reducida.
DE69938435D1 (de) 1998-10-30 2008-05-08 Novozymes As Niedrigallergene Proteinvarianten
AU1262900A (en) 1998-11-06 2000-05-29 Novo Nordisk A/S Method for the production of fvii
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
EP2319541A1 (en) * 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7220837B1 (en) * 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
EP2226385B1 (en) 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Human Coagulation Factor VII Variants
KR100882482B1 (ko) * 2000-09-13 2009-02-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 사람 응고 인자 ｖｉｉ 변이체
CA2422214A1 (en) * 2000-10-02 2002-04-11 Novo Nordisk A/S Factor vii glycoforms
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
AU2002249096B2 (en) 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
PL368619A1 (en) 2001-09-27 2005-04-04 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
CA2470511C (en) 2001-12-21 2014-05-27 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
BR0309576A (pt) * 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
CA2502162C (en) * 2002-09-30 2014-04-15 Maxygen Holdings Ltd. Fvii or fviia variants having increased clotting activity
ES2386010T3 (es) * 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
US20060116324A1 (en) * 2003-06-13 2006-06-01 Novo Nordisk Healthcare A/G Novel formulations
KR101191779B1 (ko) * 2003-06-19 2013-01-14 맥시겐 홀딩스 엘티디 인자 ⅶ 또는 ⅶ에이 지엘에이 도메인 변종들

Also Published As

Publication number Publication date
AU2010200793A1 (en) 2010-03-25
CA2529828A1 (en) 2004-12-23
RU2373282C2 (ru) 2009-11-20
BRPI0411650A (pt) 2006-08-08
AU2010200793B2 (en) 2013-04-04
US20050164932A1 (en) 2005-07-28
SI1644504T1 (sl) 2010-06-30
US8987202B2 (en) 2015-03-24
JP4915918B2 (ja) 2012-04-11
US7807638B2 (en) 2010-10-05
AU2004247799A1 (en) 2004-12-23
NZ544728A (en) 2009-04-30
CY1109984T1 (el) 2014-09-10
HK1095357A1 (en) 2007-05-04
CA2529828C (en) 2013-01-15
IL172364A (en) 2014-01-30
US20070117756A1 (en) 2007-05-24
JP2012105650A (ja) 2012-06-07
US20060241041A1 (en) 2006-10-26
DE602004025576D1 (de) 2010-04-01
DK1644504T3 (da) 2010-05-25
CN1839203B (zh) 2011-11-16
KR101191779B1 (ko) 2013-01-14
US20060240526A1 (en) 2006-10-26
US20060252128A1 (en) 2006-11-09
CN1839203A (zh) 2006-09-27
NZ573412A (en) 2010-09-30
PL1644504T3 (pl) 2010-08-31
RU2006101391A (ru) 2006-06-10
EP1644504B1 (en) 2010-02-17
EP1644504B8 (en) 2010-06-02
ZA200600539B (en) 2006-12-27
HRP20100264T1 (hr) 2010-08-31
ES2338425T3 (es) 2010-05-07
MXPA05013769A (es) 2006-03-08
AU2004247799B2 (en) 2009-12-03
JP2006527982A (ja) 2006-12-14
PT1644504E (pt) 2010-03-22
KR20060022283A (ko) 2006-03-09
JP5580283B2 (ja) 2014-08-27
WO2004111242A1 (en) 2004-12-23
EP1644504A1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
BR0215622A (pt) Inibidores da dpiv com base em glutaminila
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
MXPA02009567A (es) Benzoilpirzoles y su uso como herbicidas.
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
MXPA06003474A (es) Agonistas de receptores de melanocortina.
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
UA91680C2 (ru) Производные сульфаматов и сульфамидов для лечения эпилепсии и сопутствующих расстройств
GB0111186D0 (en) Novel compounds
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
ES2177316T3 (es) Anticuerpos humanos antifacotores ix/ixa.
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
BR0213072A (pt) Sabonete em barra
DE60228878D1 (de) Proteine mit il-6 inhibitorischer wirkung
WO2003047507A3 (en) Factor viii c2 domain variants
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
IL162600A0 (en) Cc-chemokine mutants as cc-chemokine antagonists
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
BRPI0409586A (pt) ácidos hidroxámicos úteis no tratamento de distúrbios hiperproliferativos
EA200600956A1 (ru) Молекулы-антагонисты цитокинов
ATE328602T1 (de) Kombinationspräparat zur behandlung des diabetes mellitus
IN2009CN00831A (OSRAM)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1644504

Country of ref document: EP